Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
Authors
Keywords
Renal cell carcinoma, Adjuvant therapy, Targeted therapy, Tyrosine kinase inhibitor, Immunotherapy, Immune checkpoint inhibitor
Journal
CANCER TREATMENT REVIEWS
Volume 97, Issue -, Pages 102207
Publisher
Elsevier BV
Online
2021-04-14
DOI
10.1016/j.ctrv.2021.102207
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
- (2021) Robert J. Motzer et al. EUROPEAN UROLOGY
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant therapy in high-risk renal cell cancer: A systematic review and cumulative meta-analysis.
- (2020) Rabbia Siddiqi et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of adjuvant vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (VEGFRi) in renal cell carcinoma (RCC): A systematic review and meta-analysis.
- (2020) Tobias Engel Ayer Botrel et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
- (2020) Laure Hirsch et al. DRUGS
- Genomic profiling in renal cell carcinoma
- (2020) Nazli Dizman et al. Nature Reviews Nephrology
- Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients
- (2020) Idir Ouzaid et al. Frontiers in Surgery
- Association between age and sex and mortality after adjuvant therapy for renal cancer
- (2019) Ronac Mamtani et al. CANCER
- A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)
- (2019) Axel Bex et al. Future Oncology
- Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
- (2019) Laurence Albiges et al. EUROPEAN UROLOGY
- Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study
- (2018) Daniel J. George et al. CLINICAL CANCER RESEARCH
- Validation of the 16-Gene Recurrence Score in patients with locoregional, high-risk renal cell carcinoma from a phase 3 trial of adjuvant sunitinib
- (2018) Brian I. Rini et al. CLINICAL CANCER RESEARCH
- Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
- (2018) Cora N. Sternberg et al. CLINICAL CANCER RESEARCH
- Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis
- (2018) Maxine Sun et al. EUROPEAN UROLOGY
- Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results
- (2018) Robert J. Motzer et al. EUROPEAN UROLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Role of Stereotactic body radiation therapy in the management of oligometastatic renal cell carcinoma
- (2018) Ciro Franzese et al. JOURNAL OF UROLOGY
- Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
- (2018) M Gross-Goupil et al. ANNALS OF ONCOLOGY
- Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study
- (2018) Cedric Lebacle et al. BJU INTERNATIONAL
- Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
- (2018) Daniel J. George et al. CLINICAL CANCER RESEARCH
- Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies
- (2017) Chiara Ciccarese et al. EUROPEAN JOURNAL OF CANCER
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
- (2017) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Treatment for High-Risk Clear Cell Renal Cancer
- (2017) Naomi B. Haas et al. JAMA Oncology
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
- (2016) Naomi B Haas et al. LANCET
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
- (2016) Alain Ravaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies
- (2015) Brian Rini et al. LANCET ONCOLOGY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
- (2015) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
- (2014) Samira A. Brooks et al. EUROPEAN UROLOGY
- Targeted therapies and the treatment of non-clear cell renal cell carcinoma
- (2013) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
- (2013) A. W. MacFarlane et al. Cancer Immunology Research
- The Effect of Sunitinib on Primary Renal Cell Carcinoma and Facilitation of Subsequent Surgery
- (2012) Brian I. Rini et al. JOURNAL OF UROLOGY
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started